Get the Stockscreener App
1.62
1.22%
-0.02
Neumora Therapeutics Inc stock is traded at $1.62, with a volume of 338.80K.
It is down -1.22% in the last 24 hours and down -14.29% over the past month.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
See More
Previous Close:
$1.64
Open:
$1.66
24h Volume:
338.80K
Relative Volume:
0.24
Market Cap:
$262.35M
Revenue:
-
Net Income/Loss:
$-274.18M
P/E Ratio:
-0.6392
EPS:
-2.5346
Net Cash Flow:
$-198.33M
1W Performance:
-0.61%
1M Performance:
-14.29%
6M Performance:
-10.00%
1Y Performance:
-85.91%
1-Day Range:
$1.61
$1.70
1-Week Range:
$1.56
$1.70
52-Week Range:
$0.611
$17.19
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Name
Neumora Therapeutics Inc
Sector
Industry
Phone
(857) 760-0900
Address
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Compare NMRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.62 | 265.59M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Downgrade | BofA Securities | Buy → Underperform |
| Mar-10-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-07-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-25 | Downgrade | Stifel | Buy → Hold |
| Jan-02-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-05-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Oct-10-23 | Initiated | BofA Securities | Buy |
| Oct-10-23 | Initiated | Guggenheim | Buy |
| Oct-10-23 | Initiated | JP Morgan | Overweight |
| Oct-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-10-23 | Initiated | Stifel | Buy |
| Oct-10-23 | Initiated | William Blair | Outperform |
View All
Neumora Therapeutics Inc Stock (NMRA) Latest News
Neumora Therapeutics Initiates Phase 1 Study for Schizophrenia Drug NMRA-861 - Yahoo Finance
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
What are Neumora Therapeutics Inc.’s earnings expectationsJuly 2025 Gainers & Weekly High Potential Alerts - newsyoung.net
Black Diamond Therapeutics And 2 Promising Penny Stocks For Savvy Investors - simplywall.st
Understanding Neumora Therapeutics Inc.’s price movementJuly 2025 Earnings & Weekly Chart Analysis and Guides - Newser
Volume spikes in Neumora Therapeutics Inc. stock – what they meanQuarterly Trade Summary & Real-Time Volume Surge Alerts - Newser
Does Neumora Therapeutics Inc. qualify in momentum factor screeningJuly 2025 Analyst Calls & Real-Time Stock Price Movement Reports - Newser
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Holdings Boosted by XTX Topco Ltd - MarketBeat
Can Neumora Therapeutics Inc. recover in the next quarterWeekly Risk Report & Target Return Focused Picks - Newser
Pattern recognition hints at Neumora Therapeutics Inc. upside - Newser
What makes Neumora Therapeutics Inc. stock price move sharplyLong Setup & Low Risk High Win Rate Picks - Newser
Will Neumora Therapeutics Inc. rebound enough to break even2025 Key Lessons & Safe Investment Capital Preservation Plans - Newser
Neumora Therapeutics Inc. stock trend outlook and recovery pathWeekly Stock Recap & Low Risk Entry Point Guides - Newser
Are Bears Losing Grip on Neumora Therapeutics Inc.Forecast Cut & Safe Capital Investment Plans - metal.it
Key metrics from Neumora Therapeutics Inc.’s quarterly dataTreasury Yields & Fast Entry High Yield Stock Tips - Newser
How institutional ownership impacts Neumora Therapeutics Inc. stockJuly 2025 Momentum & Daily Profit Focused Screening - Newser
What data driven models say about Neumora Therapeutics Inc.’s future - Newser
Chart based exit strategy for Neumora Therapeutics Inc.Insider Buying & Advanced Swing Trade Entry Plans - Newser
Is Neumora Therapeutics Inc. forming a reversal patternDay Trade & Real-Time Market Trend Scan - Newser
Published on: 2025-08-15 11:05:55 - beatles.ru
Federated Hermes Inc. Invests $285,000 in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Research Analysts Issue Forecasts for NMRA Q3 Earnings - MarketBeat
William Blair Has Positive Forecast for NMRA Q3 Earnings - MarketBeat
What MACD signals say about Neumora Therapeutics Inc.2025 Top Decliners & Long-Term Safe Investment Plans - Newser
William Blair Has Positive Estimate for NMRA FY2029 Earnings - MarketBeat
Best data tools to analyze Neumora Therapeutics Inc. stockBuy and Exit Strategy Based on Momentum - Newser
How Neumora Therapeutics Inc. stock reacts to Fed policy changesFree Market Surge Signal for Swing Traders - Newser
Neumora's Q2 2025 Earnings Call: Unpacking Key Contradictions in M4 PAM Safety, Obesity Focus, and KOASTAL Studies - AInvest
Neumora Therapeutics reports Q2 EPS (33c), consensus (37c) - MSN
Elevidys sales weaken; Neumora gets into obesity - BioPharma Dive
Neumora Therapeutics Faces Challenges as It Transitions to Full Public Company Compliance - TipRanks
Neumora Therapeutics’ Earnings Call Highlights Promising Pipeline - TipRanks
Neumora outlines six upcoming clinical catalysts and prioritizes obesity program with NMRA-215 - MSN
Stifel maintains Hold rating on Neumora Therapeutics stock at $2.00 By Investing.com - Investing.com Canada
Promising Developments and Pipeline Progress Drive Buy Rating for Neumora Therapeutics - TipRanks
Neumora Therapeutics, Inc.: Promising Potential in Obesity Therapeutics with NMRA-215 - TipRanks
Earnings call transcript: Neumora Therapeutics beats Q2 2025 EPS estimates - Investing.com
Neumora Therapeutics Reports Q2 2025 Financial Results - TipRanks
Neumora Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
Neumora Therapeutics (NMRA) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Neumora Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Neumora Therapeutics Inc Stock (NMRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neumora Therapeutics Inc Stock (NMRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BERNS PAUL L | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
13,871 |
23,468 |
7,405,004 |
| Milligan Michael Lee | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
1,978 |
3,351 |
22,470 |
| Aurora Daljit Singh | Chief Strategy Officer |
Feb 18 '25 |
Sale |
1.68 |
8,565 |
14,347 |
88,935 |
| Lenz Robert A. | Head of R&D |
Feb 18 '25 |
Sale |
1.67 |
5,614 |
9,383 |
309,092 |
| Pinto Joshua | President |
Feb 18 '25 |
Sale |
1.67 |
8,048 |
13,477 |
76,952 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):